Go Pro

GSK (GSK) 10K Form and Latest SEC Filings 2026

GSK logo
$48.14 +0.02 (+0.03%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$48.12 -0.01 (-0.02%)
As of 09/11/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest GSK SEC Filings & Recent Activity

GSK (NYSE:GSK) has submitted 1,665+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in GSK's financial statements. The most recent filing was a Form 6-K submitted on September 11, 2026.

20-F
GSK Files Annual Report on Mar. 6, 2026

The 20-F contains GSK's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

GSK SEC Filing History

Browse GSK's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/11/2026 9:30 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/10/2026 9:31 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/10/2026 7:53 AM
GLAXOSMITHKLINE CAPITAL INC (1224462) Filer
GSK (1131399) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
09/10/2026 5:09 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 9:45 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 9:31 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/09/2026 5:19 AM
GSK (1131399) Subject
Form FWP
09/08/2026 8:06 AM
GLAXOSMITHKLINE CAPITAL INC (1224462) Filer
GSK (1131399) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
09/08/2026 7:27 AM
GLAXOSMITHKLINE CAPITAL INC (1224462) Filer
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2026 11:26 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/01/2026 6:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Shocking AI prediction from the “Billionaire Whisperer" (Ad)

Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.tc pixel

Watch Chaikin's free presentation and see the ticker now
08/26/2026 9:37 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 9:35 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 5:57 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/24/2026 5:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/20/2026 10:19 AM
GSK (1131399) Subject
Martinez Maria E (1761768) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/18/2026 9:34 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/13/2026 3:32 PM
GSK (1131399) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
08/13/2026 10:33 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/11/2026 10:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/03/2026 10:16 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/30/2026 11:25 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/22/2026 11:52 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/20/2026 9:13 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2026 6:14 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2026 5:50 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/16/2026 9:45 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2026 8:11 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2026 8:00 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
07/14/2026 10:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/13/2026 10:28 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/13/2026 5:29 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2026 7:44 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
07/10/2026 7:13 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2026 10:27 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2026 6:27 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2026 3:44 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
07/01/2026 9:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2026 9:25 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/29/2026 9:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2026 9:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
The income “unicorn” Todd Phillips has been waiting 2 years to see again (Ad)

Retirement income specialist Todd Phillips once tracked an unusual income vehicle nicknamed the 10.3 percent Unicorn. It vanished from the market within 12 to 18 months, with no warning. Now a similar structure has resurfaced, one Todd calls the 10.3 percent War Bond, built for investors who want dependable income without tracking the stock market daily. Todd says the current rate ranks among the highest hes seen in 30 years.tc pixel

Click here to see the 10.3 percent War Bond Blueprint now
06/24/2026 3:03 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T/A
06/24/2026 9:39 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 9:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/24/2026 6:15 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-T
06/23/2026 10:05 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/22/2026 10:00 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2026 11:20 AM
GSK (1131399) Filer
Form 11-K
Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)  
06/17/2026 11:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2026 11:04 AM
GSK (1131399) Filer
Form 11-K
Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)  
06/15/2026 9:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/12/2026 5:32 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/11/2026 9:42 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/10/2026 3:54 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-C
06/10/2026 9:36 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2026 4:20 PM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-C
06/09/2026 12:37 PM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/09/2026 6:13 AM
GSK (1131399) Filed by
Nuvalent, Inc. (1861560) Subject
Form SC TO-C
06/09/2026 5:18 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 9:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/01/2026 9:00 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2026 5:02 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/27/2026 9:34 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 9:23 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/26/2026 9:17 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/22/2026 6:19 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/20/2026 9:39 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/20/2026 9:40 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2026 10:01 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 10:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/18/2026 5:29 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2026 3:45 PM
GSK (1131399) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
05/14/2026 11:22 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 9:59 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 5:42 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 5:31 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2026 12:52 PM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2026 10:18 AM
FMR LLC (315066) Filed by
GSK (1131399) Subject
Form SCHEDULE 13G
05/05/2026 11:54 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2026 10:08 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/01/2026 10:11 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 11:00 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2026 7:09 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2026 10:18 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2026 6:24 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/27/2026 7:13 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/27/2026 5:58 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2026 10:20 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2026 5:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/22/2026 5:06 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/21/2026 5:03 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Gold led me to Mount Rushmore (Ad)

A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel

Watch the free video and get the stock name now
04/20/2026 11:46 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 5:37 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/20/2026 5:19 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2026 5:16 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2026 12:01 PM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2026 5:42 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2026 5:39 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2026 5:05 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/14/2026 10:22 AM
GSK (1131399) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

GSK SEC Filings - Frequently Asked Questions

GSK (GSK) has submitted 1,665+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

GSK's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on GSK's financial statements page.

The most recent filing was a Form 6-K submitted on September 11, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NYSE:GSK are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/11/2026. New filings are added as they're published.
From Our Partners